Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q4 FY26 Earnings Presentation
18 slides from Gland Pharma's earnings presentation, May 15, 2026
Slide 1: Investor Presentation Q4 FY26 & FY26
GLAND PHARMA Investor Presentation Q4 FY26 & FY26 15th May 2026
Slide 2: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 3: Financial Highlights
in Financial Highlights
Slide 4: Consolidated P&L Highlights
Consolidated P&L Highlights ₹ Mn Particulars Q4 FY26 Q4 FY25 YoY Q3 FY26 QoQ FY26 FY25 YoY Revenue from operations 17,428 14,249 22% 16,954 3% 64,307 56,165 14% Other Income 1,115 440 153% 632 76% 3,163 2,136 48% Total Income 18,543 14,689 26% 17,585 5% 67,470 58,301 16% Gross Profit(1) 11,515 9,370
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue from Operations Gross Profit(1) / Gross Profit Margin(2) (₹ Mn) (₹ Mn / %) 64,307 56,165 41,877 35,261 65% 63% 14,249 16,954 17,428 11,187 11,515 9,370 66% 66% 66% Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Adj. EBITDA(3) / Adj. EBIT
Slide 6: Base Business (Gland) P&L Highlights
Base Business (Gland) P&L Highlights ₹ Mn Particulars Q4 FY26 Q4 FY25 YoY Q3 FY26 QoQ FY26 FY25 YoY Revenue from operations 12,648 10,332 22% 11,790 7% 45,613 41,248 11% Other Income 1,072 436 146% 631 70% 3,120 2,079 50% Total Income 13,720 10,768 27% 12,421 10% 48,733 43,327 12% Gross Profit(1) 7,
Slide 7: Base Business (Gland) Financial Highlights
Base Business (Gland) Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin(2) (₹ Mn) (₹ Mn / %) 27,662 45,613 41,248 23,943 61% 58% 7,147 7,800 11,790 12,648 6,280 10,332 61% 62% 61% Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Adj. EBITDA(3) / A
Slide 8: Group Financial Highlights (1/2)
Group Financial Highlights (1/2) Net Worth(1) ROCE(2) / RONW(3) (₹ Mn) (%) RoCE RoNW 87,238 91,507 1,03,580 11% 15.0% 12% 9% 10.0% 9% 11% 8% 5.0% 0.0% FY24 FY25 FY26 FY24 FY25 FY26 Capital Expenditure Asset Turnover Ratio(4)(5) (₹ Mn) (x) 3,975 3,938 4,938 1.5 1.5 1.4 0.6 0.5 0.5 Total asset turnove
Slide 9: Group Financial Highlights (2/2)
Group Financial Highlights (2/2) Cash and Bank Balances / Net Cash(1) Cash Flow from Operations (₹ Mn) Total Cash (₹ Mn) Net Cash 9,968 10,314 9,147 33,591 31,157 25,562 22,870 18,394 15,197 FY24 FY25* FY26 FY24 FY25 FY26 . * Excluding non-callable deposits of INR 3,960 million. Net Working Capital(
Slide 10: Business Update
in Business Update
Slide 11: Base Business (Gland) Updates
Base Business (Gland) Updates • R&D Expenses: Total R&D expenses were ₹506 million in Q4 FY26, representing 4% of base business revenue. The R&D expenditure was mainly focused on complex product development and number of filings. • New Launches: The company launched five molecules in the USA this qu
Slide 12: Cenexi Updates
Cenexi Updates Q4 FY26 Q4 FY25 Q3 FY26 FY26 FY25 Particulars YoY QoQ YoY € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. Revenue from operations 45 4,780 43 3,917 22% 50 5,164 -7% 182 18,693 164 14,916 25% Gross Margin 35 3,714 34 3,089 20% 39 4,040 -8% 139 14,216 125 11,318 26% % margin
Slide 13: Geographical Revenue
SS Geographical — Revenue |
Slide 14: US Market
US Market ₹ Mn Group Revenue Contribution Gland Cenexi 24% YoY 13% YoY 26% YoY 11% YoY -55% YoY 66% YoY 34,214 33,181 30,387 29,766 1,033 621 7,918 8,685 9,807 7,714 8,290 9,716 395 204 91 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 US Filing
Slide 15: Europe Market
Europe Market ₹ Mn Group Revenue Contribution Gland Cenexi 36% YoY 34% YoY 15% YoY 21% YoY 40% YoY 36% YoY 14,035 1,883 1,555 12,152 10,470 8,915 4,071 3,814 593 462 3,478 3,352 2,801 402 2,399 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Euro
Slide 16: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Group Revenue Contribution Gland Cenexi -2% YoY 12% YoY -24% YoY -1% YoY 56% YoY 40% YoY 2,269 1,374 1,366 903 2,021 647 601 588 437 332 256 454 288 164 166 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26
Slide 17: Rest of the World
Rest of the World ₹ Mn Group Revenue Contribution Gland Cenexi 6% YoY 3% YoY 17% YoY 7% YoY -6% YoY -3% YoY Own Products TT & CMO 6,066 6,511 4,734 4,606 10,800 11,117 1,047 1,145 1,254 1,876 1,468 2,404 3,000 2,549 4,921 5,464 1,150 1,124 1,081 326 119 1,135 1,550 1,125343 Q4 FY25 Q3 FY26 Q4 FY26 F
Slide 18: Thank You
GLAND PHARMA Thank You Corporate Office Investor Relations: Gland Pharma Limited Sampath Kumar Pallerlamudi Plot No. 11 & 84, TSIIC Phase: IV Company Secretary & Compliance Officer Pashamylaram (V), Patancheru (M), Sangareddy District Shriniwas P. Dange Hyderabad 502307, Telangana, India Investor Re